Drug Profile
Oncolysin M
Alternative Names: Anti-CD33-bR; Anti-My9-blocked ricin; Anti-My9-bRLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Dana-Farber Cancer Institute; ImmunoGen
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action CD33 antigen inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 25 Nov 1998 Discontinued-I for Acute myeloid leukaemia in Canada (Unknown route)
- 25 Nov 1998 Discontinued-I for Acute myeloid leukaemia in USA (Unknown route)